Tranche Update on Zynex, Inc.'s Equity Buyback Plan announced on November 1, 2023.
April 30, 2024 at 05:01 pm EDT
Share
From January 1, 2024 to March 31, 2024, the company has repurchased 887,820 shares, representing 2.66% for $10.41 million. With this, the company has completed the repurchase of 1,900,020 shares, representing 5.64% for $20 million under the buyback announced on November 1, 2023.
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Companyâs devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâs products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter.
ZYNEX, INC. 
